Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
NCT05695417
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-proliferative Diabetic Retinopathy
Interventions
DRUG:
OTX-TKI
DRUG:
Sham
Sponsor
Ocular Therapeutix, Inc.